-
InnoCare Releases 2023 Results and Business Highlights
PharmaSources
March 29, 2024
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
-
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Biotech Newswire
March 27, 2024
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents.
-
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
PharmaSources
March 27, 2024
Two companies have jointly begun a demonstration experiment of a cloud endoscopy system that enables image processing on the cloud.
-
Avantor Wins Five Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2024
PharmaSources
March 21, 2024
Recognition reinforces Avantor's commitment to innovation and leadership for biopharma advancement.
-
Single Use Support Opens US Office
Biotech Newswire
March 15, 2024
Fluid and cold chain management expert Single Use Support has opened a subsidiary in Lexington, Massachusetts.
-
Viroclinics-DDL Changes Name to Cerba Research
Biotech Newswire
March 15, 2024
Viroclinics-DDL proudly announces changing its name to Cerba Research as of the 1st of April 2024.
-
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Biotech Newswire
March 15, 2024
This collaborative effort will leverage ProBioGen's cutting-edge GlymaxX® technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels.
-
ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network
Biotech Newswire
March 13, 2024
The Ginkgo Technology Network brings together a diverse array of partners, spanning AI, genetic medicines, biologics, and manufacturing.
-
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China
Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
-
Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD
Chunhua Lu
March 11, 2024
Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial.